DNAH12 and glioblastoma: Six genes, namely, DMD, DNAH12, HUWE1, MYCBP2, SLC11A2, and ZFC3H1, were mutated in all patients with a good CAN008 response, and their mutation frequencies in the 366-TCGA-GBM cohort were 3.6% (13/366), 0.5% (2/366), 2.2% (8/366), 1.1% (4/366), 0.3% (1/366), and 1.4% (5/366), respectively.